Cetilistat could become first obesity drug in Japan as Takeda files for approval
This article was originally published in Scrip
Executive Summary
Takeda has filed for the approval in Japan of the lipase inhibitor cetilistat, seeking regulatory clearance for the treatment of obesity with complications including type 2 diabetes and dyslipidaemia.